Sequential detection of alphafetoprotein-bearing cells in blood stem cell fraction of germ cell tumour patients by Kasahara, T et al.
Autologous transplantation of peripheral blood stem cells (PBSC),
harvested following priming chemotherapy and granulocyte
colony-stimulating factor (G-CSF), can endure myeloablative
doses of anti-cancer drugs (Elias et al, 1995; Fields et al, 1995).
High-dose chemotherapy (HDC) combined with autologous bone
marrow transplantation (BMT) or PBSC transplantation (PBSCT)
has considerable efficacy for the treatment of patients with testic-
ular germ cell tumours (GCT) who do not achieve a disease-free
state after conventional-dose chemotherapy (Nichols et al, 1992;
Beyer et al, 1997; Broun et al, 1997). PBSCT has been increas-
ingly used in place of BMT. The advantages of this method over
BMT are (1) no need to perform collection under general anaes-
thesia, (2) the possibility of harvesting progenitor cells in patient
with bone marrow fibrosis resulting from pelvic irradiation and (3)
more rapid haematopoietic recovery (Armitage, 1994). 
However, one concern is that inadvertent reinfusion of tumour
cells contaminating the preparations of PBSC may contribute to
disease relapse. Reinfusion of malignant cells in autologous BMT
has been shown to contribute to disease recurrence in some
haematological tumours (Brenner et al, 1993; Rill et al, 1994).
Although PBSCT is believed to have a lower risk of contamination
by tumour cells (range 4–20%) than BMT according to some
previous studies using histological or immunocytochemical tech-
niques (Fields et al, 1996; Passos-Coelho et al, 1996; Schulze et al,
1997), recent studies demonstrated a higher frequency than
expected, adopting more sensitive reverse transcription polymerase
chain reaction (RT-PCR) based methods for detecting mRNA of
tumour cell-derived products (Mattano et al, 1992; Craig et al,
1994; Vannucchi et al, 1998). 
In the present study, using nested RT-PCR for detecting alpha-
fetoprotein (AFP) mRNA, we obtained evidence of tumour cell
contamination in PBSC fractions from advanced GCT patients.
Furthermore, we also found that the amount of AFP mRNA
decreased with repeated cycles of combined chemotherapy. 
MATERIALS AND METHODS 
Patient samples 
We evaluated, retrospectively, PBSC frozen samples from 5
patients with advanced testicular GCT and elevated serum AFP
(range 26–44 years old, mean age 32). The clinical stages and
pathological diagnoses are shown in Table 1. All patients had
visceral involvement and/or lymph node (LN) metastasis. They
had undergone orchiectomy, and received 3 cycles of a conven-
tional chemotherapy regimen, EP or BEP (VP-16 100 mg m–2,
cisplatin 20 mg m–2 and bleomycin 30 U) (Table 2). Mobilization
of haematopoietic stem cells in the peripheral blood was
performed by daily injections of recombinant G-CSF (75 µ gm –2
filgrastim/day–1, s.c. or 100 µ gm –2 lenograstim  day–1, s.c.) until
the number of leukocytes reached 10 000 µ l–1. Mononuclear cells
(MNC) were collected using an AS104 separator, and 7.2 litres of
blood was processed per leukopheresis. Each MNC fraction was
centrifuged, resuspended in albumin, DMSO and starch mixture,
and stored at –80˚C until use. Two or 3 consecutive leukophereses
per cycle were performed to harvest a total of more than 2 × 106
CD34 + cells per kg of body weight. 
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After conventional chemotherapy, 4 of 5 patients were treated with
HDC, which consisted of VP-16 (320 mg m–2), ifosfamide (2 g m–2)
and carboplatin (320 mg m–2) on days -6 to -2 (patient 5 died
before HDC due to carcinomatous meningitis). At the time of
transplant, one or two subsets of harvested cells (total number of
CD34+ cells was 2 × 106 per kg of body weight) were reinfused to
each patient (Table 3). 
RNA isolation from PBSC harvests 
RNA was isolated from 1 ml of processed fraction containing
approximately 1 × 107 MNC, which was aliquoted at PBSC collec-
tion. Cells were thawed in a 37˚C water bath, and wahsed once in
sterile phosphate-buffered saline (PBS). Cells were processed
using the SV total RNA isolation system (Promega, Madison, WI)
according to the manufacturer’s instructions, and resuspended in
100 µ l of diethyl pyrocarbonate-treated (DEPC) water. 
Cell line 
The Hep 3B human hepatocellular carcinoma cell line, which
secretes AFP, was used as a control (Knowles et al, 1980; Jiang 
et al, 1997). The cell line was kindly provided by Dr Toshio Kudo
(Institute of Development, Aging and Cancer, Tohoku University,
Sendai, Japan). Cells were cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum in 5% CO2/ 95% air at
37˚C. To check the sensitivity of the assay, 1 × 107 peripheral
MNC from a healthy volunteer were mixed with serial dilutions of
Hep 3B cells (1 × 103–100). 
Nested RT-PCR amplification of AFP mRNA 
cDNA synthesis and RT-PCR were performed as described previ-
ously (Bilim et al, 1998). Briefly, aliquots of 8.2 µ l RNA were
used and synthesis of cDNA was performed in a 20-µ l reaction
using a first-strand cDNA synthesis kit (Boehringer Mannheim,
Indianapolis, IN). The mixture was incubated at 25˚C for 10
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Table 1 Characteristics, at diagnosis, of patients with germ cell tumours 
Patient Age Testis cancer Histological  Site of metastasis 
no. (years) stage (UICC) analysis 
1 34 IIIC EC>T>S RP, Liver 
2 27 IIIC EC+T+CC RP, Liver 
3 44 IIB S>EC RP 
4 26 IIIA EC+YST+CC+T  RP, Supraclavicular LN 
5 31 IIIC EC RP, Axillary LN, Maxillary sinus 
EC = embryonal carcinoma; T = teratoma; S = seminoma; CC = choriocarcinoma; YST = yolk sac tumour; RP = retroperitoneal
lymph node; LN = lymph node.
Table 2 Prior treatment and serum AFP level 
Patient Induction Response Serum AFP 
no. chemotherapy (normal value < 10 ng ml–1) 
Diagnosis Harvest 1 Harvest 2  Harvest 3 
1 EPX3 PR 16 763 10 131 820 ND 
2 EPX3 PR 1851 1156 53 12 
3 EPX3 PR 29 11 5 5 
4 EPX3 NC 110 29 31 22 
5 BEPX3 PR X 10 ND <1 
Patients described in Table 1. EP: VP-16, cisplatin; BEP: bleomycin, VP-16, cisplatin; CR = complete remission; PR = partial
remission; NC = no change; Harvest 1–3: harvest during the first, second and third cycle of chemotherapy, respectively; 
X: not measured; ND: PBSC apheresis during that cycle was not performed. 
Table 3 Nested RT-PCR results and clinical course after PBSCT 
Patient no. 1st chem. 2nd chem. 3rd chem.  Transplanted PBSC Status 
1 (+) (+) NA Harvest 2  Deada
(2 of 2 subsets) 
2 (+) NA (+) Harvest 1  NED 
(2 of 2 subsets) 
3 NA (+) (–) Harvest 3  NED 
(2 of 3 subsets) 
4 NA (+) (–) Harvest 3  NED 
(1 of 2 subsets) 
5 (+) NA (–) ND Deadb
(+): AFP mRNA positive; (–): AFP mRNA negative; NA: sample not available; Harvest: PBSCs described in Table 2; 
ND: not done; a: died 3 days after PBSCT due to infection; b: died due to carcinomatous meningitis.minutes and then at 42˚C for 60 minutes. The reaction was stopped
by enzyme inactivation at 95˚C for 5 minutes. Before analysis,
amplification of the constitutively expressed β -actin gene was
performed to ensure appropriate first-strand cDNA synthesis. 
The nested PCR was conducted by adding 1 µ l of cDNA to
50 µ l of reaction buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl2 and 200 mg ml–1 gelatin), with 200 µ M of each
dNTP, 400 nM of each outer primer and 2.5 units of AmpliTaq
Gold™ (Perkin Elmer, Branchburg, NJ). 40 cycles of 1 min denat-
uration at 94˚C, 1 min annealing at 52˚C and 1 min extension step
at 72˚C were performed in a thermal cycler (Perkin Elmer). A
sample of 1 µ l of the first amplification product was subjected to
the nested amplification using inner primer pairs with the same
reagents and protocol. The amplified products were analysed by
electrophoresis on a 3% agarose gel. Two sets of primers specific
for the AFP cDNA sequence were designed (Morinaga et al,
1983). The outer pair of primers were sense: 5′ -ACTGAATCCA-
GAACACTGCATAG-3′ (nucleotides 90–112, in exon 1) and anti-
sense: 5′ -TGCAGTCAATGCATCTTTCACCA-3′ (nucleotides
263–241, in exon 3). The inner pair of primers were sense:
5’-TGGAATAGCTTCCATATTGGATTC-3′ (nucleotides 122–145,
over exon 1 and exon 2, antisense: 5′ -AAGTGGCTTCTTGAA-
CAAACTGG-3′ (nucleotides 222–200, in exon 3) (Komeda et al,
1995). Since the inner sense primer was designed to bridge the
intron, the competition of contaminating genomic DNA could be
eliminated. The identity of the amplified products was confirmed
by direct sequencing (data not shown). Each PCR reaction was
performed in triplicate to confirm the accuracy of the findings. 
RESULTS 
Specificity and sensitivity of the nested RT-PCR assay
for AFP 
Using cDNA from Hep 3B cells, which secrete AFP, specific
bands (101 bp) were detected (Figure 1). Peripheral MNC
obtained from healthy volunteers (approximately 1 × 107 cells)
were used as the negative control. We also examined PBSC frac-
tions from 3 other patients whose primary testicular tumours did
not contain AFP-producing cells (two of them were diagnosed as
seminoma and one was choriocarcinoma). No detectable mRNA
was found in the harvests obtained after any cycle of conventional
chemotherapy (data not shown). 
The sensitivity of the nested PCR was determined by simulating
a contamination model with a different number of Hep 3B cells
into MNC obtained from a healthy volunteer. As few as 10 Hep 3B
cells were detected among 1 × 107 MNC (Figure 1). 
Nested PCR analysis of PBSC fractions from AFP
producing GCT patients 
The patient characteristics are summarized in Table 1. In the
primary tumours, the presence of embryonal carcinoma (EC)
and/or yolk sac tumour (YST), either of which may produce AFP,
was confirmed histopathologically. In all patients, AFP mRNA
was detected in PBSC fractions harvested after the first and second
cycle of conventional chemotherapy. In contrast, in 3 of 4 samples
obtained after the third cycle, AFP mRNA was not detected
(Figure 2, patients 3–5). 
Comparison between AFP mRNA detection and serum
AFP levels 
PBSC apheresis during elevated serum AFP (over 10 ng ml–1)
resulted in detection of AFP mRNA-bearing cells in PBSC 
fractions in all cases except one. Patient 4 was the only exception.
His serum AFP remained high even after HDC, but AFP mRNA in
PBSC fraction after the third cycle of induction chemotherapy was
not detected. On CT he had cystic residual tumours. Surgical
resection of the residual tumours revealed a cystic mass without
viable cancer cells, which contained fluid with a high concentra-
tion of AFP, leading to elevated serum AFP. As for patient 3,
serum AFP decreased to within the normal range by the time of the
second cycle of chemotherapy, but AFP mRNA was detected in
the PBSC fraction obtained after that cycle. 
Clinical course after HDC with PBSCT 
Patient 5, who had multiple LNs and maxillary sinus metastasis,
did not receive HDC because he had achieved clinical complete
AFP detection in PBSC fraction by RT-PCR 1121
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Figure 1 Sensitivity of nested PCR for detection of AFP mRNA. Peripheral
mononuclear cells (1 × 107) were mixed with 103, 102, 101 and 100 Hep 3B
cells. RNA was isolated from each mixture, and cDNA was prepared using
random primers. Nested PCR using AFP primers was performed. The 176
and 101 base pair fragments were amplified from outer and inner primer
pairs, respectively (upper). In all samples, the presence of adequately
amplified mRNA had been assessed by RT-PCR of the β -actin gene (lower).
Lane M: 100 base pairs DNA marker (New England Biolabs, Massachusetts) 
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Figure 2 Detection of AFP mRNA in PBSC fractions from advanced GCT
patients and peripheral blood mononuclear cells (PBMC) from a healthy
volunteer, using nested RT-PCR (upper). The amplification of the β -actin
gene by RT-PCR (lower). Marker: 100 base pairs DNA marker (New England
Biolabs). First figure corresponds to a patient; second corresponds to a
chemotherapy cycle number remission by administration of 3 cycles of chemotherapy.
However, he died due to carcinomatous meningitis 5 months after
the end of chemotherapy without evidence of involvement of other
organs. The remaining 4 patients underwent HDC with PBSCT
following induction chemotherapy because of partial remission
or no clinical response (details of PBSC infusion are shown in
Table 3). Patient 1 died during the myelosuppression phase (3 days
after PBSCT) due to infection. Two patients (patients 3–4)
received resection of residual tumours after HDC. Those tumours
did not contain cancer cells histopathologically. Those patients
remained alive without disease (mean follow up 36 months).
Retrospectively, however, patient 2 was transplanted with AFP
mRNA positive fraction (Table 3) although he was alive without
evidence of recurrence (more than 5 years). 
DISCUSSION 
Although RT-PCR can detect tumour cells with higher sensitivity
than the histological or immunocytochemical methods which have
been commonly used (Mapara et al, 1997; Vannucchi et al, 1998),
low specificity remains a problem (Ghossein et al, 1999). In the
present study, to exclude false positive results, MNC from healthy
volunteers and PBSC fractions from AFP non-producing GCT
patients were examined by nested RT-PCR, but no AFP signals
were detected. Moreover, direct sequence of the amplified prod-
ucts of a positive control revealed accurate AFP cDNA. 
The sensitivity of this assay was a single tumour cell per 1 × 106
MNC. We were able to detect circulating AFP-bearing cells even
in the fraction where the serum AFP level decreased to within the
normal range during chemotherapy. Although the sensitivity of
AFP RT-PCR could be further improved (Ghossein et al, 1999), at
the present state, it might be a useful modality to predict metastatic
disease in germ cell tumours. Besides, detection of AFP mRNA-
bearing cells in PBSC fraction may reveal the presence of refrac-
tory residual disease after induction chemotherapy. 
In all samples harvested after the first and second cycle, AFP
mRNA was detected. It was shown that mRNA of β human chori-
onic gonadotropin (β -HCG), another germ cell tumour marker,
was also detected in the PBSC fractions of GCT patients (Fan et al,
1998). Moreover, in the 3 of 4 samples after the third cycle, 
AFP mRNA was not detected. Our results are in agreement 
with the clearance of circulating tumour cells in blood samples
during chemotherapy in neuroblastoma patients (Moss et al,
1990). These findings imply a possibility of reducing minimal
residual tumour cell load (i.e. in vivo purging) by multiple cycles
of conventional chemotherapy. Thus, the use of PBSCs after 3
cycles of conventional chemotherapy might reduce the possibility
of recurrence due to tumour cell contamination in the fraction,
although relapse may take place due to the tumour cells remaining
inside the body even after chemotherapy. This is supported by the
findings of Vredenburgh et al (1997), who reported that the higher
the number of tumour cells identified in the bone marrow harvest,
the shorter the disease-free and overall survival. 
A variety of techniques have been proposed to purge tumour
cells ex vivo (Gribben et al, 1991; Vogel et al, 1996; Spyridonidis
et al, 1998). Although prospective randomized trials remain to
be investigated to determine whether a positive selection of
haematopoietic progenitor cells and/or depletion of tumour cells
contaminating PBSC fraction affects clinical outcome, the combi-
nation of in vivo and ex vivo purging might become an attractive
strategy to improve patient survival. 
However, one patient who received PBSCT with AFP mRNA
positive cells remained free from recurrence after more than 5
years follow-up. Cooper et al (1998) demonstrated that tumour
cells contaminated in PBSC fractions from advanced breast cancer
patients were capable of clonogenic growth in vitro, but the
authors were unable to find a significant correlation of occult
tumour reinfusion with time to progression or overall survival.
Tumour cells contaminated in PBSC fractions may not have the
capacity to grow in vivo, possibly due to killing by host immune
cells (Kennedy et al, 1994). Thus, the presence or absence of AFP
mRNA-bearing cells may not necessarily determine recurrence of
a tumour after HDC and PBSCT. 
In summary, we showed the presence of AFP mRNA-bearing
cells in PBSC fractions from GCT patients. The nested RT-PCR
method may be useful for detecting circulating tumour cells with
high sensitivity. Furthermore, in the administration of HDC with
PBSCT, it may assist the determination of the best timing of
harvest. Although larger patient groups and different purging trials
are required, the present findings suggest that harvesting PBSC
after multiple cycles of induction chemotherapy in advanced GCT
patients might be recommended in terms of a reduced risk of
tumour cell contamination. 
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